期刊文献+

聚乙二醇干扰素治疗慢性乙型肝炎的临床疗效

下载PDF
导出
摘要 目的探讨聚乙二醇干扰素不同方案治疗慢性乙型肝炎的疗效。方法选取2009年9月至2019年2月如皋博爱医院收治的慢性乙型肝炎住院及门诊患者资料,将符合纳入条件的69例患者分为3组:单用聚乙二醇干扰素a-2a(派罗欣)的单用干扰素组22例,同步联合组24例和序贯联合组23例。对比3组在治疗24周、48周及72周时的丙氨酸氨基转移酶(ALT)、乙肝病毒的脱氧核糖核酸(HBV-DNA)和乙肝表面抗原(HBsAg)及不良反应发生情况。结果单用干扰素组患者24周、48周及72周的ALT均值高于同步联合及序贯联合组,HBV-DNA转阴数、HBsAg均值均低于同步联合组及序贯联合组,差异有统计学意义(P<0.05),而同步联合组与序贯联合组比较,差异无统计学意义(P>0.05)。3组不良反应发生率比较,差异无统计学意义(P>0.05)。结论对于慢性乙型肝炎患者,同步或序贯联合法治疗在生化学、病毒学应答方面优于单用聚乙二醇干扰素治疗。
作者 田广
机构地区 如皋博爱医院
出处 《现代医学与健康研究电子杂志》 2019年第12期20-21,24,共3页 Modern Medicine and Health Research
  • 相关文献

参考文献4

二级参考文献37

  • 1Hong-Zhu Lu,Jian-Hua Zhou.Hepatitis B virus X protein up-regulates tumor necrosis factor-α expression in cultured mesangial cells via ERKs and NF-κB pathways[J].Asian Pacific Journal of Tropical Biomedicine,2013,3(3):217-222. 被引量:16
  • 2中华医学会肝病学分会 中华医学会感染病学分会.慢性乙型肝炎防治指南.中华肝脏病杂志,2010,19(1):3760-3769.
  • 3Tseng T C, Liu C J, Chen C L, et al. Serum hepatitis B virus- DNA levels correlate with long-term adverse outcomes in sponta- neous hepatitis B e antigen seroconverters [ J ]. J Infect Dis, 2012,205 ( 1 ) :54.
  • 4Xu L, Yin W, Sun R,et al. Kupffer cell-derived IL-10 plays a key role in maintaining hmnoral immune tolerance in hepatitis B virus-persistent mice[ J]. Hepatology,2014,59(2) :445.
  • 5Li C, Ji H, Cai Y, et al. Serum interleukin-37 concentrations and HBeAg seroconversion in chronic HBV patients during telbivudine treatment [ J ]. J Interferon Cytokine Res, 2013,22 (5) :114.
  • 6Chang TT,Liaw YF,Wu SS,et al.Long-term entecavir therapy results in the reversal of fiborsis/cirrhosis and continued histological improvement in patients with chronic hepatitis B[J].Hepatology,2010,52:886-893.
  • 7Marcellin P,Bonino F,Yurdaydin C,et al.Hepatitis B surface antigen levels:association with 5-year response to peginterferon alfa-2ain hepatitis B e-antigen-negative patients[J].Hepatol Int,2013,7:88-97.
  • 8Zoutendijk R,Reijnders JG,Zoulim F,et al.Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis[J].Gut,2013,62:760-765.
  • 9Masataka T,Eisuke M,Michio I,et al.Serum HBV RNA and HBeAg are useful markers for the safe discontinuation of nucleotide analogue treatments in chronic hepatitis B patients[J].J.Gastroenterol,2013,48:1188-1204.
  • 10Kim SS,Cheong JY,Lee D,et al.Adefovir-based combination therapy with entecavir or lamivudine for patients with entecavir-refractory chronic hepatitis B[J].J Med Virol,2012,84:18-25.

共引文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部